Examining the Role of Sensitivity to Uncertain Threat and Alcohol Response in Risk for Alcohol Use Disorder Following Sexual Assault in College Women
The goal of this clinical trial is to determine whether women who engage in heavy drinking with a history of sexual assault (SA) victimization show heightened baseline reactivity to uncertain threat (U-threat), whether alcohol reduces this reactivity and related anxiety, and how these processes link to real-world drinking behavior. The main questions it aims to answer are:
- Test whether heavy drinking women with a history of SA display exaggerated baseline reactivity to U-threat.
- In the lab, test whether alcohol intoxication is associated with decreases in reactivity to U-threat and subjective anxiety, particularly in heavy drinking women with a history of SA.
- In the real-world, test associations between SA victimization, reactivity to U-threat, alcohol consumption, and anxiolytic relief.
Participants will:
- Complete a screening and orientation session
- Complete two experimental lab sessions that will include intravenous (IV) administration of either 80mg% alcohol or placebo (saline), order counterbalanced
- Complete daily ecological momentary assessments (EMA) surveys for 21 days
- Wear a transdermal alcohol wrist biosensor (BACTrack Skyn) for 21-days
調査の概要
研究の種類
入学 (推定)
段階
- 初期フェーズ 1
連絡先と場所
研究連絡先
- 名前:Stephanie Gorka
- 電話番号:614-366-1027
- メール:stephanie.gorka@osumc.edu
研究場所
-
-
Ohio
-
Columbus、Ohio、アメリカ、43210
- 募集
- Ohio State University
-
コンタクト:
- Stephanie Gorka
- 電話番号:614-366-1027
- メール:stephanie.gorka@osumc.edu
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
General Inclusion Criteria for All Participants:
- Biological female
- 21-29 years old
- At least a high school education
- Fluency in English
- Heavy drinker as defined as 8 or more alcoholic drinks per week and at least two binge episodes (4 or more drinks for in a 2-hour period) in the past month
Additional Inclusion Criteria for Heavy Drinkers with History of Sexual Assault (HD+SA) Group:
- Self-reported experience of sexual assault victimization after age 14.
Additional Inclusion Criteria for Heavy Drinkers without History of Sexual Assault (HD-SA) Group:
- No exposure to lifetime DSM-5 Criterion A traumatic stressor. Participants will not be excluded for accidents, injuries, or witnessing community violence to ensure the sample is representative.
Exclusion Criteria for All Participants:
- Any serious medical problems (e.g., liver disease, cardiac abnormality, pancreatitis, diabetes, neurological problems, and gastrointestinal disorders)
- Body weight < 110 or > 210 lbs
- Current medical or psychiatric condition requiring medication for which alcohol consumption is contraindicated
- Substance use disorder other than mild and moderate alcohol use disorder
- Positive urine screen for drugs other than cannabis
- Currently seeking or past-12-month history of inpatient or intensive treatment for addictive behaviors
- Pregnancy, nursing, or planning to become pregnant in the next 3 months
- Report smoking more than 5 cigarettes (or electronic equivalent) per day
- Lifetime history of psychosis.
Additional Exclusion Criteria for HD+SA Group:
- Report a first onset SA within the past 30 days
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:基礎科学
- 割り当て:ランダム化
- 介入モデル:クロスオーバー割り当て
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
他の:Heavy Drinking with a History of Sexual Assault Victimization (HD+SA)
Participants in this group will be required to be biological females between the ages of 21-29 who engage in heavy drinking with a history of sexual assault victimization after age 14. |
Participants receive placebo (saline) intravenously. Participants will receive 80 mg% intravenous alcohol. |
|
他の:Heavy Drinking without a History of Sexual Assault Victimization (HD-SA)
Participants in this group will be required to be biological females between the ages of 21-29 who engage in heavy drinking either without a history of sexual assault victimization after age 14. |
Participants receive placebo (saline) intravenously. Participants will receive 80 mg% intravenous alcohol. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Startle eyeblink potentiation during the threat task
時間枠:Baseline (Visit 1), approximately 7 days later (Visit 2), and approximately 14 days after baseline (Visit 3)
|
Startle eyeblink potentiation will be collected during the NPU threat task that is administered at all three lab sessions. Startle is a cross-species index of aversive reactivity. |
Baseline (Visit 1), approximately 7 days later (Visit 2), and approximately 14 days after baseline (Visit 3)
|
|
Subjective affective response to alcohol in the lab
時間枠:At the Placebo and Alcohol sessions (Visits 2 and 3), approximately 7 days apart.
|
Participants will complete the Profile of Mood States (POMS) throughout the placebo and alcohol administration protocols. The Profile of Mood States Anxiety subscale consists of 9 items, with each item rated from 0 (not at all) to 4 (extremely), resulting in a total score ranging from 0 to 36. Higher scores indicate greater subjective anxiety, while lower scores indicate less subjective anxiety. The Anxiety subscale will serve as the primary measure of subjective anxiety and will be compared between the placebo and alcohol sessions. |
At the Placebo and Alcohol sessions (Visits 2 and 3), approximately 7 days apart.
|
|
Subjective effects of alcohol in the lab
時間枠:At the Placebo and Alcohol sessions (Visits 2 and 3), approximately 7 days apart.
|
Participants will rate the degree to which they 'feel', 'like', and 'want more' of the infused substance on a visual analogue scale ranging from 0 ('not at all') to 100 ('extremely'). The 'like' and 'want more' scales will serve as the primary measures of drug liking and drug wanting, respectively. |
At the Placebo and Alcohol sessions (Visits 2 and 3), approximately 7 days apart.
|
|
Ecological momentary assessment (EMA) of affective response to alcohol in the real world
時間枠:Assessed daily for 21-days
|
Up to five times per day, participants will complete ecological momentary assessments (EMA) of their current anxiety, distress, and other mood states. Participants will rate each emotion on a 0-5 scale, where 0 = not at all and 5 = extremely. Affect will be assessed during periods of sobriety and intoxication. |
Assessed daily for 21-days
|
|
Transdermal alcohol concentration (TAC)
時間枠:Assessed daily for 21-days
|
Participants' TAC will provide an objective estimate of alcohol consumption. |
Assessed daily for 21-days
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- 2024H0264
- 1R01AA032115-01A1 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
De-identified data, including startle eyeblink and behavior, from this project will be submitted to the The National Institute on Alcohol Abuse and Alcoholism Data Archive (NIAAADA) at the subject level along with appropriate supporting documentation to enable efficient use of the data by the research community. We will follow instructions as discussed in the NDA Data Sharing Terms and Conditions.
IPD 共有時間枠
The data will be submitted biannually.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。